FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (clinicaltrials.gov) - Sep 23, 2026 - P3 | N=466 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting
Enrollment open • Fibrosis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases
|